Helix Acquisition CORP Ii 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported encouraging early clinical data for its oncology pipeline and completed a significant de-SPAC transaction, bolstering its financial position for future development.
Helix Acquisition Corp. II details its outstanding Class A and Class B ordinary shares, preference shares, and related shareholder rights in its annual 10-K filing.